SELECT trial: difference between revisions
Diff·revision 10 → 11·14:31, 4 Jan 2025
Difference between revision 10 and revision 11 of SELECT trial. 9 lines changed; the page grew by 630 bytes.
| Revision 10 — 21:18, 17 Dec 2024 OpenLabelOtto (talk) fix the anchor on an internal link 3,547 bytes +45 | Revision 11 — 14:31, 4 Jan 2025 SelectTrialSam (talk) add the comparator arm — an event rate alone says nothing 4,177 bytes +630 | ||
|---|---|---|---|
| 31 | Separation of the event curves began early, within the first months, before the majority of weight loss had occurred. Whether the benefit is mediated by weight reduction, by direct vascular effects, by improvements in blood pressure and inflammatory markers, or by some combination is not established by the trial.{{r|lincoff2023}} | 31 | Separation of the event curves began early, within the first months, before the majority of weight loss had occurred. Whether the benefit is mediated by weight reduction, by direct vascular effects, by improvements in blood pressure and inflammatory markers, or by some combination is not established by the trial.{{r|lincoff2023}} |
| 32 | 32 | ||
| + | 33 | The [[Number needed to treat|number needed to treat]] can be computed from the absolute risk difference of 1.5 percentage points over roughly 3.3 years, giving approximately 67 over that period. Absolute rather than relative figures are what allow benefit and harm to be compared on the same scale.{{r|nnt_ref}} | |
| + | 34 | ||
| 33 | == References == | 35 | == References == |
| 34 | {{reflist}} | 36 | {{reflist}} |
| ⋮ | ⋮ | ||
| 36 | <ref name="marso2016s">Marso SP, Bain SC, Consoli A, et al. "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes." ''New England Journal of Medicine'' 375(19):1834–1844 (2016). PMID 27633186.</ref> | 38 | <ref name="marso2016s">Marso SP, Bain SC, Consoli A, et al. "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes." ''New England Journal of Medicine'' 375(19):1834–1844 (2016). PMID 27633186.</ref> |
| 37 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> | 39 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> |
| + | 40 | <ref name="nnt_ref">Laupacis A, Sackett DL, Roberts RS. "An assessment of clinically useful measures of the consequences of treatment." ''New England Journal of Medicine'' 318(26):1728–1733 (1988). PMID 3374545.</ref> | |
| + | 41 | ||
| + | 42 | == See also == | |
| + | 43 | * [[Semaglutide]] | |
| + | 44 | * [[STEP trial programme]] | |
| + | 45 | * [[LEADER trial]] | |
| + | 46 | * [[FLOW trial]] | |
| 38 | 47 | ||
| 39 | {{DEFAULTSORT:SELECT trial}} | 48 | {{DEFAULTSORT:SELECT trial}} |